Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The purpose of this study was to optimize a peptide (nABP284) that binds to programmed cell death protein 1 (PD-1) by a computer-based protocol in order to increase its affinity. Then, this study aimed to determine the inhibitory effects of this peptide on cancer immune escape by coculturing improving cytokine-induced killer (ICIK) cells with cancer cells. Materials and methods: nABP284 that binds to PD-1 was identified by phage display technology in our previous study. AutoDock and PyMOL were used to optimize the sequence of nABP284 to design a new peptide (nABPD1). Immunofluorescence was used to demonstrate that the peptides bound to PD-1. Surface plasmon resonance was used to measure the binding affinity of the peptides. The blocking effect of the peptides on PD-1 was evaluated by a neutralization experiment with human recombinant programmed death-ligand 1 (PD-L1) protein. The inhibition of activated lymphocytes by cancer cells was simulated by coculturing of human acute T lymphocytic leukemia cells (Jurkat T cells) with human tongue squamous cell carcinoma cells (Cal27 cells). The anticancer activities were determined by coculturing ICIK cells with Cal27 cells in vitro. Results: A high-affinity peptide (nABPD1, KD=11.9 nM) for PD-1 was obtained by optimizing the nABP284 peptide (KD=11.8 μM). nABPD1 showed better efficacy than nABP284 in terms of increasing the secretion of interkeulin-2 by Jurkat T cells and enhancing the in vitro antitumor activity of ICIK cells. Conclusion: nABPD1 possesses higher affinity for PD-1 than nABP284, which significantly enhances its ability to block the PD-1/PD-L1 interaction and to increase ICIK cell-mediated antitumor activity by armoring ICIK cells.
Abstract
Purpose: The purpose of this study was to optimize a peptide (nABP284) that binds to programmed cell death protein 1 (PD-1) by a computer-based protocol in order to increase its affinity. Then, this study aimed to determine the inhibitory effects of this peptide on cancer immune escape by coculturing improving cytokine-induced killer (ICIK) cells with cancer cells. Materials and methods: nABP284 that binds to PD-1 was identified by phage display technology in our previous study. AutoDock and PyMOL were used to optimize the sequence of nABP284 to design a new peptide (nABPD1). Immunofluorescence was used to demonstrate that the peptides bound to PD-1. Surface plasmon resonance was used to measure the binding affinity of the peptides. The blocking effect of the peptides on PD-1 was evaluated by a neutralization experiment with human recombinant programmed death-ligand 1 (PD-L1) protein. The inhibition of activated lymphocytes by cancer cells was simulated by coculturing of human acute T lymphocytic leukemia cells (Jurkat T cells) with human tongue squamous cell carcinoma cells (Cal27 cells). The anticancer activities were determined by coculturing ICIK cells with Cal27 cells in vitro. Results: A high-affinity peptide (nABPD1, KD=11.9 nM) for PD-1 was obtained by optimizing the nABP284 peptide (KD=11.8 μM). nABPD1 showed better efficacy than nABP284 in terms of increasing the secretion of interkeulin-2 by Jurkat T cells and enhancing the in vitro antitumor activity of ICIK cells. Conclusion: nABPD1 possesses higher affinity for PD-1 than nABP284, which significantly enhances its ability to block the PD-1/PD-L1 interaction and to increase ICIK cell-mediated antitumor activity by armoring ICIK cells.
참고문헌 (30)
- Riley RS, "Delivery technologies for cancer immunotherapy", Nat Rev Drug Discov, 18, pp.175~196 (2019)
- Yang Y, "Cancer immunotherapy : harnessing the immune system to battle cancer", J Clin Invest, 125, pp.3335~3337 (2015)
- Keir ME, "PD-1 and its ligands in tolerance and immunity", Annu Rev Immunol, 26, pp.677~704 (2008)
- Pauken KE, "Overcoming T cell exhaustion in infection and cancer", Trends Immunol, 36, pp.265~276 (2015)
- Topalian SL, "Immune checkpoint blockade : a common denominator approach to cancer therapy", Cancer Cell, 27, pp.450~461 (2015)
- Larkin J, "Combined nivolumab and ipilimumab or monotherapy in untreated melanoma", N Engl J Med, 373, pp.23~34 (2015)
- Robert C, "Pembrolizumab versus ipilimumab in advanced melanoma", N Engl J Med, 372, pp.2521~2532 (2015)
- Garon EB, "Pembrolizumab for the treatment of non-small-cell lung cancer", N Engl J Med, 372, pp.2018~2028 (2015)
- Morgensztern D, "Nivolumab and pembrolizumab for non-small cell lung cancer", Clin Cancer Res, 22, pp.3713~3717 (2016)
- Yang J, "Immunomodulators targeting the PD-1", PD-L1 protein-protein interaction : from antibodies to small molecules, 2019, pp.39, 265~301
- Ruoslahti E, "Peptides as targeting elements and tissue penetration devices for nanoparticles", Adv Mater, 24, pp.3747~3756 (2012)
- Fosgerau K, "Peptide therapeutics : current status and future directions", Drug Discov Today, 20, pp.122~128 (2015)
- Zak KM, "Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1", Structure, 23, pp.2341~2348 (2015)
- Lim H, "Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method", Sci Rep, 9, pp.16727~ (2019)
- Biesiada J, "Survey of public domain software for docking simulations and virtual screening", Hum Genomics, 5, pp.497~505 (2011)
- Martinez X, "Molecular graphics : bridging structural biologists and computer scientists", Structure, 27, pp.1617~1623 (2019)
- Pan K, "Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer", Clin Cancer Res, 20, pp.3003~3011 (2014)
- Lee JH, "Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma", Gastroenterology, 148, pp.1383~1391 (2015)
- Huang X, "Rescue of iCIKs transfer from PD-1", PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma(TSCC), 2018, pp.59, 127~133
- Jiang P, "Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC", Int Immunopharmacol, 28, pp.208~214 (2015)
- Maute RL, "Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging", Proc Natl Acad Sci U S A, 112, pp.E6506~E6514 (2015)
- Saw PE, "Phage display screening of therapeutic peptide for cancer targeting and therapy", Protein Cell, 10, pp.787~807 (2019)
- Johnston RJ, "VISTA is an acidic pH-selective ligand for PSGL-1", Nature, 574, pp.565~570 (2019)
- Cheng X, "Structure and interactions of the human programmed cell death 1 receptor", J Biol Chem, 288, pp.11771~11785 (2013)
- Zorzi A, "Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides", Nat Commun, 8, pp.16092~ (2017)
- Yao JF, "Metabolism of peptide drugs and strategies to improve their metabolic stability", Curr Drug Metab, 19, pp.892~901 (2018)
- Tian Y, "Thioether-derived macrocycle for peptide secondary structure fixation", Chem Rec, 17, pp.874~885 (2017)
- Ganesan P, "Investigation of structural stability and functionality of homodimeric gramicidin towards peptide-based drug : a molecular simulation approach", J Cell Biochem, 120, pp.4903~4911 (2019)
- Estrella V, "Acidity generated by the tumor microenvironment drives local invasion", Cancer Res, 73, pp.1524~1535 (2013)
- Gauthier L, "Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity", Cell, 177, pp.1701~1713 (2019)